⏰ TL;DR (Too Long; Didn't Read)

💡The Idea

• Pre-operative surgical plans are often neglected due to the difficulty and time-consuming nature of existing software, surgeons' heavy workloads, lack of hospital support, and absence of financial incentives for creating such plans.
• Kavilab develops DeepPLAN, a suite of solutions that leverage artificial intelligence to automate and enhance preoperative surgical planning in orthopedics. DeepPLAN includes:
• DeepPLAN K: AI-based digital templating for Total Knee Arthroplasty (TKA)
• DeepPLAN T: Preoperative surgical simulator for orthopedic trauma
• DeepPLAN A: Interactive medical image control software
• DeepPLAN F: Virtual Surgical Planning (VSP) system for orthopedic trauma
• These solutions utilize deep learning, 3D imaging, and Monte Carlo simulations to provide comprehensive surgical planning tools.

🥇Benefits

• Time Efficiency: Automated planning in 3-5 minutes vs. 30 minutes to 4 hours for manual methods
• Accuracy: AI-driven analysis for precise surgical plans and implant selection
• Patient-Specific Approach: Customized planning and potential for patient-specific implants
• Versatility: Utilizes both CT and X-ray data
• User-Friendly: Offers both installation and web viewer options
• Comprehensive: Includes features like auto-segmentation, auto-reduction, and implant simulation

💵Business Model

• In Korea: Pay per use on a per-operation basis (approx. $1,000).
• In US: business model under development
• Marketing strategy:
• Partnerships with / Indirect sales through multinational vendors, pharmaceutical/medical device companies, and distributors
• Direct sales to hospitals

🌎Market data

• iMarc: The global preoperative surgical planning software market size reached US$267.1 million in 2023. Looking forward, the market is expected to reach $1,746.8 million by 2032, exhibiting a growth rate (CAGR) of 22.51% during 2024-2032 (source)
• TAM based on number of operations: TBD

🚀Status

• DeepPLAN K: Revenue Generation expected (Second half 2024)
• Need more clarity here - what is developed, what connections are live, etc…

📋Regulation

• Korea
• Ministry of Food and Drug Safety (MFDS) approval obtained for DeepPLAN K in April 2024
• DeepPLAN T: Clinical Trial initiated in May 2024, MFDS Approval expected in second half of 2024
• EU / US - in early stages of application for regulatory approval

📣Promotional materials